Analysts Offer Predictions for CRSP Q1 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, February 11th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings per share of ($1.33) for the quarter. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.30) EPS, Q3 2025 earnings at ($1.26) EPS, Q4 2025 earnings at ($1.26) EPS and FY2026 earnings at ($5.17) EPS.

CRSP has been the subject of a number of other reports. TD Cowen upgraded CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective for the company in a research report on Wednesday. Royal Bank of Canada reduced their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a report on Wednesday. Barclays lifted their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a report on Wednesday. Truist Financial lifted their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday. Finally, The Goldman Sachs Group reduced their price target on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a report on Thursday. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $74.05.

CRISPR Therapeutics Trading Up 0.4 %

Shares of NASDAQ CRSP opened at $43.49 on Thursday. CRISPR Therapeutics has a one year low of $36.52 and a one year high of $91.10. The firm has a market capitalization of $3.71 billion, a PE ratio of -15.37 and a beta of 1.67. The business has a 50-day moving average price of $42.06 and a two-hundred day moving average price of $46.25.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the transaction, the chief executive officer now directly owns 181,540 shares in the company, valued at $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CRSP. Highline Wealth Partners LLC acquired a new position in shares of CRISPR Therapeutics in the fourth quarter valued at $39,000. Western Pacific Wealth Management LP raised its stake in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of CRISPR Therapeutics in the third quarter valued at $40,000. Darwin Wealth Management LLC acquired a new position in shares of CRISPR Therapeutics in the third quarter valued at $43,000. Finally, Eastern Bank acquired a new position in shares of CRISPR Therapeutics in the third quarter valued at $70,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.